13F Holdings
中文EN

ENTA ENANTA PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1177648 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.7%
TTM net income YoY31.3%
TTM EPS YoY44.0%
Revenue 3-yr CAGR-6.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-90.0%
Net margin-96.9%
FCF margin-56.6%
EBITDA margin-82.5%

Returns

ROE-70.1%
ROA-21.2%
ROIC (approx.)-90.9%
Asset turnover0.22x

Leverage & solvency

Liabilities / assets66.0%
Debt / equity0.00x
Current ratio3.76x
Interest coverage-4.55x

Cash quality & payout

Operating cash flow / net income0.56x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue$65.32M$67.64M$79.20M$86.16M$97.07M
R&D expense$106.74M$131.48M$163.52M$164.52M$174.11M
SG&A expense$43.93M$57.85M$52.89M$45.48M$32.54M
Operating income-$85.35M-$121.69M-$137.21M-$123.84M-$109.57M
Interest expense$7.68M$10.94M$5.15M$0$0
Pretax income-$83.55M-$117.79M-$131.00M-$122.19M-$107.58M
Income tax-$1.66M-$1.74M$2.82M-$433,000-$28.58M
Net income-$81.89M-$116.05M-$133.82M-$121.75M-$79.00M
EBITDA-$80.76M-$119.36M-$134.84M-$120.87M-$106.24M
EPS (basic)-3.84-5.48-6.38-5.91-3.92
EPS (diluted)-3.84-5.48-6.38-5.91-3.92
Weighted avg. shares (diluted)21,33621,15720,96920,60320,171
Balance sheet
Cash & equivalents$32.30M$37.23M$85.39M$43.99M$57.21M
Short-term investments$156.57M$210.95M$284.52M$205.24M$186.80M
Receivables$6.88M$6.65M$8.61M$20.32M$23.58M
Current assets$204.34M$299.85M$422.79M$311.71M$319.02M
PP&E, net$35.40M$32.69M$11.92M$6.17M$5.94M
Total assets$280.73M$376.65M$462.27M$375.41M$438.79M
Current liabilities$48.55M$57.53M$62.79M$29.83M$36.17M
Total liabilities$216.01M$247.84M$245.54M$54.08M$39.36M
Shareholders' equity$64.72M$128.81M$216.74M$321.33M$399.43M
Shares outstanding21.39M21.39M21.06M20.79M20.24M
Cash flow statement
Operating cash flow-$19.27M-$78.76M-$103.15M-$84.78M-$70.00M
Capital expenditure$12.90M$17.95M$9.06M$2.12M$750,000
Free cash flow-$32.17M-$96.71M-$112.21M-$86.91M-$70.75M
Investing cash flow$40.35M$58.23M-$53.58M$54.90M$36.99M
Financing cash flow-$26.62M-$27.63M$198.13M$20.03M$3.08M
Depreciation & amortization$4.59M$2.34M$2.37M$2.97M$3.33M
Stock-based compensation$18.57M$26.80M$28.22M$26.97M$20.99M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.